Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer

Overview

Journal Front Pharmacol

Date 2019 Jun 28

PMID 31244652

Citations 52

Authors

Srinivas Patnaik

Anupriya

Affiliations

Soon will be listed here.

Abstract

Genetic variations along with epigenetic modifications of DNA are involved in colorectal cancer (CRC) development and progression. CRC is the fourth leading cause of cancer-related deaths worldwide. Initiation and progression of CRC is the cumulation of a variety of genetic and epigenetic changes in colonic epithelial cells. Colorectal carcinogenesis is associated with epigenetic aberrations including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs. Recently, epigenetic modifications have been identified like association of hypermethylated gene Claudin11 (CLDN11) with metastasis and prognosis of poor survival of CRC. DNA methylation of genes CMTM3, SSTR2, MDF1, NDRG4 and TGFB2 are potential epigenetic biomarkers for the early detection of CRC. Tumor suppressor candidate 3 (TUSC3) mRNA expression is silenced by promoter methylation, which promotes epidermal growth factor receptor (EGFR) signaling and rescues the CRC cells from apoptosis and hence leading to poor survival rate. Previous scientific evidences strongly suggest epigenetic modifications that contribute to anticancer drug resistance. Recent research studies emphasize development of drugs targeting histone deacetylases (HDACs) and DNA methyltransferase inhibitors as an emerging anticancer strategy. This review covers potential epigenetic modification targeting chemotherapeutic drugs and probable implementation for the treatment of CRC, which offers a strong rationale to explore therapeutic strategies and provides a basis to develop potent antitumor drugs.

Citing Articles

Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies.

Tahghighi A, Seyedhashemi E, Mohammadi J, Moradi A, Esmaeili A, Pornour M Clin Epigenetics. 2025; 17(1):34.

PMID: 39987205 PMC: 11847397. DOI: 10.1186/s13148-025-01844-w.

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities.

Cai W, Cai X, Fei Y, Ye R, Song D, Hu D Front Oncol. 2025; 15:1534055.

PMID: 39980537 PMC: 11839428. DOI: 10.3389/fonc.2025.1534055.

Epigenetic modulation of autophagy pathway by small molecules in colorectal cancer: a systematic review.

Zamani M, Safari F, Siri M, Igder S, Khatami N, Dastghaib S J Cancer Res Clin Oncol. 2024; 150(10):474.

PMID: 39441422 PMC: 11499346. DOI: 10.1007/s00432-024-05982-1.

Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors.

Pekkarinen M, Nordfors K, Uusi-Makela J, Kytola V, Hartewig A, Huhtala L Life Sci Alliance. 2024; 7(6).

PMID: 38499326 PMC: 10948937. DOI: 10.26508/lsa.202302088.

Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.

Kumari R, Syeda S, Shrivastava A Curr Med Chem. 2024; 31(32):5281-5304.

PMID: 38425113 DOI: 10.2174/0109298673282525240222050051.

References

Hong S . Genetic and epigenetic alterations of colorectal cancer. Intest Res. 2018; 16(3):327-337. PMC: 6077299. DOI: 10.5217/ir.2018.16.3.327. View

Bubna A . Vorinostat-An Overview. Indian J Dermatol. 2015; 60(4):419. PMC: 4533557. DOI: 10.4103/0019-5154.160511. View

Zhijun H, Shusheng W, Han M, Jianping L, Li-Sen Q, Dechun L . Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016; 37(8):10257-67. DOI: 10.1007/s13277-016-4868-6. View

Verdone L, Agricola E, Caserta M, Di Mauro E . Histone acetylation in gene regulation. Brief Funct Genomic Proteomic. 2006; 5(3):209-21. DOI: 10.1093/bfgp/ell028. View

Maes T, Carceller E, Salas J, Ortega A, Buesa C . Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol. 2015; 23:52-60. DOI: 10.1016/j.coph.2015.05.009. View

Singh B, Zhang G, Hwa Y, Li J, Dowdy S, Jiang S . Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10(6):935-54. PMC: 3273412. DOI: 10.1586/era.10.62. View

Armaghany T, Wilson J, Chu Q, Mills G . Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012; 5(1):19-27. PMC: 3348713. View

Zuma A, de Oliveira Santos J, Mendes I, De Souza W, Machado C, Motta M . Chaetocin-A histone methyltransferase inhibitor-Impairs proliferation, arrests cell cycle and induces nucleolar disassembly in Trypanosoma cruzi. Acta Trop. 2017; 170:149-160. DOI: 10.1016/j.actatropica.2017.02.007. View

Martin S, Kala R, Tollefsbol T . Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation. Curr Cancer Drug Targets. 2017; 18(1):97-106. PMC: 5577390. DOI: 10.2174/1568009617666170206104032. View

10.

Richon V, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind R . A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998; 95(6):3003-7. PMC: 19684. DOI: 10.1073/pnas.95.6.3003. View

11.

De Maglio G, Casagrande M, Guardascione M, Fontanella C, Lutrino S, Rihawi K . MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol. 2015; 11(8):1201-9. DOI: 10.2217/fon.15.2. View

12.

Vitale G, Dicitore A, Pepe D, Gentilini D, Grassi E, Borghi M . Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines. Mol Oncol. 2017; 11(8):1007-1022. PMC: 5537710. DOI: 10.1002/1878-0261.12070. View

13.

Bai G, Chu J, Eli M, Bao Y, Wen H . PAQR3 overexpression suppresses the aggressive phenotype of esophageal squamous cell carcinoma cells via inhibition of ERK signaling. Biomed Pharmacother. 2017; 94:813-819. DOI: 10.1016/j.biopha.2017.07.154. View

14.

Hull E, Montgomery M, Leyva K . HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int. 2016; 2016:8797206. PMC: 4983322. DOI: 10.1155/2016/8797206. View

15.

Greer E, Shi Y . Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13(5):343-57. PMC: 4073795. DOI: 10.1038/nrg3173. View

16.

Zhou L, Cheng X, Connolly B, Dickman M, Hurd P, Hornby D . Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol. 2002; 321(4):591-9. PMC: 2713825. DOI: 10.1016/s0022-2836(02)00676-9. View

17.

Zhang Y, Wang S, Kang W, Liu C, Dong Y, Ren F . CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation. Oncogene. 2018; 37(26):3485-3500. PMC: 6021369. DOI: 10.1038/s41388-018-0161-z. View

18.

Li Q, Wei S, Li J, Chen S, Chen J, Huang H . [Decitabine Enhances the Sensitivity of Leukemia Stem Cell to Allo-NK Cell-Mediated Killing]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017; 25(1):85-89. DOI: 10.7534/j.issn.1009-2137.2017.01.014. View

19.

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F . A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006; 12(15):4628-35. DOI: 10.1158/1078-0432.CCR-06-0511. View

20.

Tumber A, Collins L, Petersen K, Thougaard A, Christiansen S, Dejligbjerg M . The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2006; 60(2):275-83. DOI: 10.1007/s00280-006-0374-7. View